NCT03934541View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

February 5, 2021

Study Completion Date

May 26, 2021

Conditions

HIV Infections

Interventions

BIOLOGICAL

MPER-656 Liposome Vaccine

Administered by intramuscular injection

BIOLOGICAL

Placebo for MPER-656 Liposome Vaccine

Administered by intramuscular injection

Trial Locations (6)

10065

New York Blood Center CRS, New York

35294

Alabama CRS, Birmingham

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

02215-4302

Fenway Health (FH) CRS, Boston

10032-3732

Columbia P&S CRS, New York

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03934541 - Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants | Biotech Hunter | Biotech Hunter